This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Psychiatry  • Attention Deficit Hyperactivity Disorder  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Intern Med. 2001;161:2501-2502.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome or hypersensitive syndrome has been associated with the use of aromatic anticonvulsants, sulfonamides, calcium channel blockers, allopurinol, ranitidine, and thalidomide. The clinical manifestations include a diffuse maculopapular rash, fever, multivisceral involvement, eosinophilia, atypical lymphocytosis, and abnormal liver function test results.¹

Nevirapine is a potent and selective noncompetitive inhibitor of the reverse transcriptase enzyme of human immunodeficiency virus (HIV) type 1, inhibiting reverse transcriptase by binding to tyrosine components of the enzyme, which are located near the catalytic site.² It was the first nonnucleoside reverse transcriptase inhibitor approved for clinical use in patients infected with HIV and is used in combination with other antiretroviral agents.^3-4

Two cases of DRESS syndrome induced by the use of zalcitabine⁵ have been reported, and 4 cases were associated with nevirapine therapy.^6-7 The following is a report of a new case of DRESS syndrome associated with nevirapine . . . [Full Text of this Article]

Report of a Case


Comment


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Persistent high nevirapine blood level with DRESS syndrome 12 days after interruption of antiretroviral therapy
Breining et al.
BMJ Case Reports 2009;2009:bcr0720080475-bcr0720080475.
ABSTRACT | FULL TEXT